- $76.79m
- -$43.76m
- 48
- 44
- 24
- 32
Annual income statement for ESSA Pharma, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 24.1 | 37.2 | 37 | 32.1 | 34.4 |
| Operating Profit | -24.1 | -37.2 | -37 | -32.1 | -34.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -23.7 | -36.8 | -35.2 | -26.6 | -28.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -23.4 | -36.8 | -35.1 | -26.6 | -28.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -23.4 | -36.8 | -35.1 | -26.6 | -28.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -23.4 | -36.8 | -35.1 | -26.6 | -28.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.04 | -0.956 | -0.797 | -0.603 | -0.645 |